High Fecal Prevalence of mcr-Positive Escherichia coli in Veal Calves at Slaughter in France

Maryse Michèle Um 1, Véronique Dupouy 2, Nathalie Arpaillange 2, Clémence Bièche-Terrier 3, Frédéric Auvray 1, Eric Oswald 1, Hubert Brugère 1 and Delphine Bibbal 1,*

1 Institut de Recherche en Santé Digestive, Université de Toulouse, INSERM, INRAE, ENVIT, UPS, 31 000 Toulouse, France
2 Innovations Thérapeutiques et Résistances, Université de Toulouse, INRAE, ENVIT, 31 000 Toulouse, France
3 Institut de l’Elevage, 75 012 Paris, France
4 CHU de Toulouse, Hôpital Purpan, 31 000 Toulouse, France
* Correspondence: delphine.bibbal@envt.fr

Abstract: The aim of this study was to determine the percentage of healthy veal calves carrying mcr-positive E. coli strains at the time of slaughter in France. Fecal samples were selectively screened for mcr-positive E. coli isolates using media supplemented with colistin. Screening for mcr genes was also carried out in E. coli isolates resistant to critically important antimicrobials used in human medicine recovered from the same fecal samples. Overall, 28 (16.5%) out of the 170 veal calves tested carried mcr-positive E. coli. As some calves carried several non-redundant mcr-positive strains, 41 mcr-positive E. coli were recovered. Thirty-one and seven strains were positive for mcr-1 and mcr-3 genes, respectively, while no strain was positive for the mcr-2 gene. Co-carriage of mcr-1 and mcr-3 was identified in three strains. All mcr-positive E. coli isolates, except one, were multidrug-resistant, with 56.1% being ciprofloxacin-resistant and 31.7% harboring blaCTX-M genes. All mcr-3-positive E. coli carried blaCTX-M genes, mainly blaCTX-M-55. This study highlights the high prevalence of mcr-positive E. coli strains in feces of veal calves at the time of slaughter. It also points out the multidrug (including ciprofloxacin) resistance of such strains and the co-occurrence of mcr-3 genes with blaCTX-M-55 genes.

Keywords: Escherichia coli; mcr genes; colistin; extended spectrum β-lactamase; critically important antibiotics; healthy veal calves

1. Introduction

Colistin is currently considered as the last-resort antibiotic for human infections due to multidrug-resistant Enterobacteriaceae, notably those producing extended spectrum β-lactamas (ESBLs) and carbapenemases [1]. Colistin has also been used in veterinary medicine, notably, as a first-intention antibiotic for treating gastrointestinal infections in food-producing animals [2]. The future usefulness of this last-resort antibiotic was challenged by the first description of a plasmid-mediated colistin resistance gene (mcr-1) [3], especially as other plasmid-mediated colistin resistance genes (mcr-2 and mcr-3) were also identified [4,5]. Up to the present, seven additional mcr genes (mcr-4 to mcr-10) have been identified [6], with mcr-1 remaining the most prevalent [7]. The most common plasmids carrying the mcr-1 gene, which are IncI2, IncHI2 and IncX4, have been shown to be highly transferable and to carry other resistance genes [8–10]. They contributed to the widespread distribution of the mcr-1 gene worldwide [6].

As food-producing animals have been identified as a possible source of transmission of colistin-resistant bacteria to humans [6], the monitoring of such strains in the food chain is required. The detection of mcr-positive E. coli in food-producing animals has been recently reviewed [11]. This review indicated that the comparison of epidemiological studies, and their reported prevalence, is often challenging due to varying study design, methodologies and reporting. The first prevalence data were mainly obtained in a diseased context and
through PCR screenings of ESBL-producing E. coli, and only a few reports focused on the detection of mcr genes in E. coli isolated from healthy animals [12]. Moreover, as only a few attempts were made to selectively isolate mcr-positive E. coli, the true prevalence of such strains in the commensal intestinal microbiota of healthy animals slaughtered for human consumption remains poorly described. This is especially true in the veal calf sector where only a few prevalence studies were conducted [11]. The monitoring of colistin resistance should be carried out in veal calves as they are frequently exposed to antibiotics, including colistin [2,13].

The objective of this study was therefore to evaluate the intestinal carriage of E. coli isolates positive for mcr-1, mcr-2 and mcr-3 by veal calves at the time of slaughter in France. A total of 170 fecal samples were selectively screened for mcr-positive E. coli isolates on colistin-supplemented media. Moreover, as co-detection of mcr genes with ESBL genes has been reported [12], ESBL-producing E. coli were also isolated from the same 170 fecal samples and screened for mcr genes. The occurrence of such genes in E. coli resistant to other critically important antimicrobials (CIA) for human medicine: ciprofloxacin and carbapenem was also investigated.

2. Results

2.1. Detection of mcr-Positive E. coli Isolates

A specific detection of mcr-positive E. coli isolates in media supplemented with colistin was performed. For 24 out of the 170 calf fecal samples, at least one E. coli was isolated from colistin-supplemented RAPID E. coli 2 agar plates which had been inoculated with colistin-supplemented BGBB turbid broths. A total of 27 presumptive colistin-resistant E. coli isolates were recovered, as 2 non-redundant isolates were obtained from 3 calves as determined by ERIC-PCR typing (data not shown). PCR screening of the mcr-1, mcr-2 or mcr-3 gene showed that 23 out of the 27 colistin-resistant E. coli isolates were mcr-positive (identified as “COL” in Table 1). These originated from 21 calves. Meanwhile, PCR screening of the mcr-1, mcr-2 and mcr-3 gene was also performed in collections of CIA-resistant E. coli isolated from the same 170 fecal calf samples. From these, 110 yielded ciprofloxacin-resistant E. coli isolates. ERIC-PCR typing led to the recovery of 172 non-redundant ciprofloxacin-resistant E. coli isolates. Twelve mcr-positive E. coli isolates were identified amongst these strains (identified as “CIP” in Table 1). At least 1 ESBL-producing E. coli from 56 fecal samples was isolated. ERIC-PCR typing led to the recovery of 69 non-redundant ESBL-producing E. coli isolates, among which 9 were positive for mcr genes (identified as “CTX” in Table 1). No E. coli isolate was recovered from ChromoID CARBA and OXA-48 media. In all, 44 mcr-positive E. coli isolates were detected, including 23 isolated from media supplemented with colistin (COL), 12 corresponding to ciprofloxacin-resistant E. coli (CIP) and 9 corresponding to ESBL-producing E. coli (CTX) (Table 1).
Table 1. Characterization of 44 mcr-positive E. coli strains isolated from French veal calves at the time of slaughter.

| Campaign ID 1 | Farm ID | Calf ID | Strain ID 2 | Isolation Medium 3 | mcr Gene | Resistance Pattern 4 | bla<sub>CTX-M</sub> Gene | PFGE Type 5 |
|---------------|---------|---------|-------------|--------------------|----------|----------------------|--------------------------|-------------|
| B2            | 13      | B2-4    | B2-4-COL-1 * | COL                | mcr-1    | AMP-STR-TET-CHL-SUL-TMP-CIP-NAL | 7            |            |
| B2-5          |         | B2-5    | B2-5-COL-1 * | COL                | mcr-1    | AMP-STR-TET-CHL-SUL-TMP-CIP-NAL | 7            |            |
|               |         |         | B2-5-CTX-1   | CTX                | mcr-1    | AMP-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| B2-6          |         | B2-6    | B2-6-COL-1   | COL                | mcr-1    | AMP-STR-TET-CHL-SUL-TMP-CIP-NAL | 7            |            |
| B2-7          |         | B2-7    | B2-7-COL-1   | COL                | mcr-1    | AMP-STR-TET-CHL-SUL-TMP-CIP-NAL | 7            |            |
| B2-8          |         | B2-8    | B2-8-COL-1   | COL                | mcr-1    | TET                   | 2             |            |
| B2-9          |         | B2-9    | B2-9-COL-1   | COL                | mcr-1    | AMP-STR-TET-CHL-SUL-TMP-CIP-NAL | 7            |            |
| B2-10         |         | B2-10   | B2-10-COL-1  | COL                | mcr-1    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
|               |         |         | B2-10-CTX-1  | CTX                | mcr-1    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
|               | 14      | B2-25   | B2-25-CTX-1  | CTX                | mcr-1    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
|               |         |         | B2-26        | CTX                | mcr-1    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A             | 32      | A12     | A12-CTX-1    | CTX                | mcr-3    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A15           |         | A15     | A15-CTX-1    | CTX                | mcr-3    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
|               | 34      | A1      | A1-CTX-2     | CTX                | mcr-1,-3 | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
|               |         | A1-CIP-1| CIP          | mcr-3              | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A             |         | A3      | A3-CTX-1     | CTX                | mcr-3    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A4            |         | A4      | A4-COL-1     | COL                | mcr-1,-3 | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A4-CTX-1      |         |         | A4-CTX-1     | CTX                | mcr-1,-3 | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A4-CIP-1      |         |         | A4-CIP-1     | CIP                | mcr-1,-3 | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A5            |         | A5      | A5-COL-1     | COL                | mcr-3    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
| A5-CTX-1      |         |         | A5-CTX-1     | CTX                | mcr-3    | AMP-STR-STR-TET-CHL-SUL-TMP-CIP-NAL |              |            |
Table 1. Cont.

| Campaign ID 1 | Farm ID | Calf ID | Strain ID 2 | Isolation Medium | mcr Gene | Resistance Pattern 4 | bla<sub>CTX-M</sub> Gene | PFGE Type 5 |
|---------------|---------|---------|-------------|------------------|----------|----------------------|--------------------------|-------------|
| B1            | 37      | B1-29   | B1-29-COL-1 * | COL              | mcr-1    | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL | 6            |             |
|               |         |         | B1-29-CIP-1 * | CIP              | mcr-1    | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL | 6            |             |
|               | 39      | B1-2    | B1-2-CIP-1   | CIP              | mcr-1    | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL | 13           |             |
| NP2           | B1-6    | B1-6-COL-1 | COL          | mcr-1          | AMP·STR·TET·SUL·TMP                  | 8            |             |
|               |         | B1-6-CIP-1 | CIP          | mcr-1          | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL  | 5            |             |
|               | B1-11   | B1-11-COL-1 | COL          | mcr-1          | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL  | 10           |             |
|               |         | B1-11-CIP-1 | CIP          | mcr-1          | AMP·STR·TET·SUL·TMP                  | 5            |             |
|               | B1-12   | B1-12-COL-1 | COL          | mcr-1          | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL  | 5            |             |
|               |         | B1-12-CIP-1 | CIP          | mcr-1          | AMP·STR·TET·SUL·TMP                  | 8            |             |
|               | B1-13   | B1-13-COL-1 | COL          | mcr-1          | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL  | NT           |             |
|               |         | B1-13-COL-6 | COL          | mcr-1          | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL  | NT           |             |
|               |         | B1-13-CIP-2 | CIP          | mcr-1          | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL  | 5            |             |
|               | B1-14   | B1-14-COL-1 | COL          | mcr-1          | AMP·STR·TET·SUL·TMP                  | 8            |             |
|               |         | B1-14-CIP-1 | CIP          | mcr-1          | AMP·GEN·STR·TET·CHL·SUL·TMP·CIP·NAL  | 5            |             |
|               | B1-15   | B1-15-COL-1 | COL          | mcr-1          | AMP·STR·TET·SUL·TMP                  | 8            |             |
|               |         | B1-15-CIP-1 | CIP          | mcr-1          | AMP·GEN·CHL·CIP·NAL                  | 5            |             |
| A2            | 41      | A2-4    | A2-4-COL-1   | COL              | mcr-1    | AMC·AMP·STR·TET·CHL·SUL·TMP·CIP·NAL | 1            |             |
|               | 42      | A2-22   | A2-22-COL-1  | COL              | mcr-1    | AMP·STR·TET·SUL·TMP                  | 14           |             |
|               |         | A2-25   | A2-25-COL-1  | COL              | mcr-1    | AMP·STR·TET·SUL·TMP                  | 14           |             |
| B3-2          | 50      | B3-2-7  | B3-2-7-COL-1 | COL              | mcr-1    | AMP·STR·TET·SUL·TMP                  | 12           |             |
|               |         | B3-2-11 | B3-2-11-COL-1 | COL           | mcr-1    | AMP·STR·TET·SUL·TMP                  | 12           |             |

1 Sampling campaigns were performed in 2017 as follows: B2, March; B3 and A, April; B1, May; A2, June; B2-2 and B3-2, September; RA, October. 2 Redundant E. coli isolates originating from the same calf are marked with an asterisk. 3 E. coli strains subjected to PCR screening for mcr genes were isolated on BGBB tubes + 2 µg/mL of colistin and then on RAPID’ E. coli 2 agar + 2 µg/mL of colistin (COL); RAPID’ E.coli 2 agar + 1 µg/mL of cefotaxime (CTX) and RAPID’ E. coli 2 agar + 1 µg/mL of ciprofloxacin (CIP). 4 AMC, amoxicillin plus clavulanic acid; AMP, ampicillin; CAZ, ceftazidime; CIP, ciprofloxacin; CHL, chloramphenicol; CTX, cefotaxime; CXM, cefuroxime; FEP, cefepime; GEN, gentamicin; LEX, cephallexin; NAL, nalidixic acid; SUL, sulfonamides; STR, streptomycin; TET, tetracycline; TMP, trimethoprim. 5 NT, Not Typed.
2.2. Characterization of mcr-Positive E. coli Isolates

The characterization of mcr-positive E. coli isolates led to the identification of redundant isolates sharing the same pulsed-field gel electrophoresis (PFGE) type, resistance pattern and mcr gene. These were isolated using colistin- and CIP-containing media from three calves (i.e., B2-4, B2-5 and B1-29; Table 1). By contrast, nine calves (i.e., B2-5, A1, A5, B1-6, B1-11, B1-12, B1-13, B1-14 and B1-15) were found to carry two non-redundant mcr-positive E. coli isolates recovered from colistin- and CIA-containing media. Lastly, for calf B2-10, two mcr-positive E. coli isolates belonging to distinct PFGE types were isolated from colistin-containing medium. The three redundant isolates were discarded from our selection of strains, which thus contained 41 mcr-positive E. coli strains isolated from 28 calves.

Thirty-one and seven E. coli isolates were positive for mcr-1 and mcr-3 genes, respectively. The remaining three isolates showed a co-occurrence of the two genes (Table 1). All mcr-positive E. coli isolates, except for one strain (B2-8-COL-1), were multidrug-resistant (MDR), and 56.1% were resistant to ciprofloxacin. None of the mcr-positive E. coli isolates was positive for plasmid-mediated quinolone resistance (PMQR) genes. ESBL was produced by 13 mcr-positive E. coli (31.7%), and bla\textsubscript{CTX-M} genes were detected in all these strains. Co-carriage of bla\textsubscript{CTX-M-1} or bla\textsubscript{CTX-M-14} and mcr-1 was observed in three strains. bla\textsubscript{CTX-M-55} was identified in nine mcr-3-positive E. coli strains, associated or not with the mcr-1 gene; bla\textsubscript{CTX-M-14} was identified in one mcr-3-positive E. coli strain.

2.3. Prevalence of mcr-Positive E. coli Calf Aiders at Alaughter

Overall, the prevalence of mcr-positive E. coli in fecal samples from healthy calves was 16.5% (28/170) (Table 2). More precisely, it was 12.9% (22/170) and 3.5% (6/170) for calf carriers of mcr-1- and mcr-3-positive E. coli isolates, respectively. Positive calves came from 10 out of the 32 farms providing calves that were tested at slaughter. Information about the use of colistin could be obtained for 25 farms with only 3 of them reporting the use of colistin. Positive calves originated from two of these farms (Table 2). PFGE analysis showed that mcr-positive E. coli strains from calves originating from the same farm commonly shared PFGE types, suggesting circulation of strains or clones within a farm and potential transmission between animals. By contrast, PFGE types were distinct between farms, except for PFGE type 1 that was identified in farms 13 and 41 (Table 1).

Table 2. Distribution of sampled calves according to campaign, farm, number of calves carrying mcr-positive E. coli and use of colistin in farms.

| Campaign ID | Farm ID | No. of Calves Carrying mcr-Positive E. coli/No. of Calves Tested | Use of Colistin ² |
|-------------|---------|---------------------------------------------------------------|------------------|
| B2          | 13      | 7/7                                                           | Y                |
|             | 14      | 2/3                                                           | N                |
| B3          | NP 29   | 0/5                                                           | NK               |
| A           | 31      | 0/5                                                           | Y                |
|             | 32      | 2/5                                                           | N                |
|             | 33      | 0/5                                                           | NK               |
|             | 34      | 4/5                                                           | N                |
|             | 35      | 0/5                                                           | N                |
|             | 36      | 0/5                                                           | N                |
| B1          | 37      | 1/6                                                           | N                |
|             | 38      | 0/4                                                           | N                |
|             | 39      | 1/5                                                           | Y                |
|             | 40      | 0/5                                                           | N                |
|             | NP 1    | 0/4                                                           | NK               |
|             | NP 2    | 6/6                                                           | NK               |
Table 2. Cont.

| Campaign ID ¹ | Farm ID | No. of Calves Carrying mcr-Positive E. coli/No. of Calves Tested | Use of Colistin ² |
|---------------|---------|-----------------------------------------------------------------|------------------|
| A2            | 41      | 1/5                                                             | N                |
|               | 42      | 2/5                                                             | N                |
|               | 43      | 0/5                                                             | N                |
|               | 44      | 0/5                                                             | N                |
|               | NP3     | 0/5                                                             | NK               |
| B2-2          | 45      | 0/6                                                             | N                |
|               | 47      | 0/6                                                             | N                |
|               | 48      | 0/3                                                             | N                |
| B3-2          | 50      | 2/6                                                             | NK               |
|               | 51      | 0/6                                                             | N                |
|               | 53      | 0/3                                                             | N                |
| RA            | 62      | 0/7                                                             | N                |
|               | 63      | 0/8                                                             | N                |
|               | 64      | 0/8                                                             | N                |
|               | 65      | 0/7                                                             | N                |
|               | NP4     | 0/5                                                             | NK               |
| Total         | 32      | 28/170                                                          |                  |

¹ Sampling campaigns were performed in 2017 as follows: B2, March; B3 and A, April; B1, May; A2, June; B2-2 and B3-2, September; RA, October. ² Use of colistin: Y, Yes; N, No; NK, Not Known.

3. Discussion

A significant number of studies on colistin resistance concentrated on pigs and chickens and highlighted high prevalence in these sectors. Fewer studies were conducted in cattle, and they tended to show low prevalence in dairy cattle [11]. The aim of our study was to accurately determine the prevalence of carriage of mcr-positive E. coli isolates by healthy veal calves at the time of slaughter. To do so, we isolated presumptive colistin-resistant E. coli by inoculating BGBB with Durham tubes supplemented with 2 µg/mL of colistin. This isolation procedure was completed by parallel screening for the presence of mcr genes in ciprofloxacin-resistant and ESBL-producing E. coli recovered from the same fecal samples. Indeed, it has been shown that plasmids carrying mcr genes also carried genes encoding resistance to various antibiotics such as cephalosporins, carbapenems and fluoroquinolones [14–16]. This multifaceted approach improved the detection of mcr-positive E. coli isolates from fecal samples.

We identified that the prevalence of mcr-positive E. coli in fecal samples from healthy calves was 16.5%, with 12.9% and 3.5% of the calves carrying mcr-1-positive and mcr-3-positive E. coli isolates, respectively. No mcr-2-positive isolate was detected here, in agreement with the detection of this gene from animals reported only in China and Belgium [4,17]. In the USA, Meinersmann et al. did not detect any mcr-positive Enterobacteriaceae when 1077 cecal contents from cattle were tested for presumptive colistin-resistant E. coli [18]. A pan-European study from 2008 to 2014 did not report any isolation of mcr-1-positive E. coli isolates when 3101 cattle were tested [19]. Reviewing the prevalence of mcr genes in cattle, Shen et al. reported that the prevalence of mcr-1 in bacteria was consistently low, from 0.5% to 0.8% in China, 2.6% in Egypt and from 0.1% to 3.3% in Europe [11]. The discrepancies between these studies and ours might partly result from the fact that mcr-positive E. coli form part of the sub-dominant fecal microbiota. The majority of prevalence studies screened for only a single E. coli isolate per animal, consequently, mcr-positive strains present in the intestinal microbiota of the animal could remain undetected and are named the ‘phantom resistome’ [20]. In our study, the use of colistin-supplemented media after an enrichment step in the presence of colistin likely increased the identification of mcr-positive E. coli isolates, which is in agreement with previous reports showing the importance of an enrichment step with colistin to detect mcr-positive E. coli [21,22]. Screening performed on
ESBL-producing or ciprofloxacin-resistant *E. coli* also contributed here to the identification of higher proportions of *mcr*-positive *E. coli* isolates in cattle and also shown by others in France. Haenni and colleagues tested 1398 ESBL producers from diseased veal calves and detected 15.0% and 2.6% of *mcr*-1- and *mcr*-3-positive *E. coli* isolates, respectively [23,24]. These higher proportions are consistent with the fact that these diseased calves might have been treated with antibiotics, and especially colistin.

Our results confirmed that *mcr*-positive isolates were resistant to other antibiotics [10,25,26]. Except for one isolate, all *mcr*-positive strains were MDR and 56.1% of them were resistant to ciprofloxacin. Regarding resistance to cephalosporins, only 15.8% of *mcr*-1-positive *E. coli* had *bla*<sub>CTX-M</sub> genes, whereas all *mcr*-3-positive *E. coli* carried such genes. The co-occurrence of *mcr*-3 genes and *bla*<sub>CTX-M-55</sub> was the most frequently observed gene combination. Although the CTX-M 55 subtype is very common in Asia and, until recently, seemed to be limited to this continent [27], the emergence of *bla*<sub>CTX-M-55</sub> associated with *mcr*-1 and/or *mcr*-3 genes was reported in France in cattle and in a pediatric infection, suggesting that CTX-M-55-producing *E. coli* could be vectors of *mcr*-3 dissemination outside Asia [23,28].

Calves harboring *mcr*-positive *E. coli* came from ten farms, from which only two reported the use of colistin in the batch from which the calves sampled at the slaughterhouses originated. Out of the 32 farms, another farm reported the use of colistin, but no calf harboring *mcr*-positive *E. coli* was detected at the time of slaughter. Since the year 2017 when the sampling was performed, the use of colistin in food animal production has drastically decreased in France and several countries around the world, in order to limit the spread of *mcr* genes [29,30]. The occurrence and distribution of *mcr* genes was monitored after the withdrawal of colistin at pig and chicken farms. Studies showed different results, and the association between colistin withdrawal and control of the spread of *mcr* genes was not evidenced [25,31–33]. It should be stressed, however, that in the absence of colistin use, treatment with other antibiotics might co-select *mcr* genes and favor their spread. Indeed, eight out the ten farms with *mcr*-positive isolates did not report the use of colistin.

In conclusion, this study revealed a high prevalence of fecal carriage of *mcr*-positive *E. coli* by healthy veal calves at the time of slaughter. It also pointed out the multidrug-resistance of such strains. Although the use of colistin has drastically decreased in food-producing animals in recent years, it should be kept in mind that the use of other antibiotics could lead to the selection of *mcr*-positive isolates. The monitoring of such strains in the food chain is still required.

4. Materials and Methods
4.1. Study Population and Sampling

Fecal samples were collected from 170 calves aged from 6 to 8 months, originating from 32 calf fattening units and intended for meat production. Feces were collected after evisceration at the time of slaughter in five French slaughterhouses (identified as A, B1, B2, B3 and RA) during 8 sampling campaigns from March to September 2017 (Table 2). A survey was conducted at the farms to identify their use of colistin in the batch from which the calves sampled at the slaughterhouses originated.

4.2. Collections of Presumptive Colistin- and CIA-Resistant *E. coli*

Feces were diluted (10 g in 90 mL) in modified tryptone soya broth (mTSB). In order to detect presumptive colistin-resistant *E. coli*, fecal samples were diluted 1:10 in brilliant green bile broth (BGBB) with Durham tubes and supplemented with 2 µg/mL of colistin. Duplicate BGBB tubes were incubated at 44 °C for 24 h. The positive BGBB tubes were then plated onto RAPID’*E. coli*2 agar (Bio-Rad®) with 2 µg/mL of colistin (COL). At the same time, CIA-resistant *E. coli* were detected by plating fecal suspensions in duplicate onto: (i) RAPID’*E. coli*2 agar (Bio-Rad®) supplemented with 1 µg/mL of cefotaxime (CTX), (ii) RAPID’*E. coli*2 agar (Bio-Rad®) supplemented with 1 µg/mL of ciprofloxacin (CIP), (iii) ChromID CARBA agar and (iv) ChromID OXA-48 agar (bioMérieux®, Marcy-l’Étoile, France). All plates were incubated overnight at 44 °C. Up to 8 *E. coli* colonies were collected...
per positive plate, confirmed for species using the indole production test and typed using the Enterobacterial Repetitive Intergenic Consensus (ERIC) -PCR fingerprinting assay with the ERIC 2 primer [34]. The DNA fingerprints of the isolates collected from each animal were visually compared to identify non-redundant resistant strains in each positive calf that was submitted for further characterization.

4.3. Screening for Plasmid-Mediated Resistance Genes

The presence of mcr-1, mcr-2 and mcr-3 genes was investigated by PCR using previously described primers and conditions [5,35]. For ESBLs producers, multiplex PCR assays were performed to detect (i) bla\textsubscript{TEM}/bla\textsubscript{SHV}/bla\textsubscript{OXA-1} genes, (ii) bla\textsubscript{CTX-M} genes and (iii) plasmid AmpC genes [36]. The products of the PCR amplification of bla\textsubscript{CTX-M} genes were purified using QIAquick\textsuperscript{®} PCR Purification Kit (QIAGEN) and subjected to bidirectional Sanger sequencing using an Applied Biosystems Analyzer 3130 xl at GeT-Purpan platform (Genotoul, Toulouse, France). The resulting data were analyzed with Sequence Scanner 2 Software and BLAST. Strains resistant to ciprofloxacin were screened for the presence of the PMQR determinants qnr\textsubscript{A}, qnr\textsubscript{B}, qnr\textsubscript{C}, qnr\textsubscript{D}, qnr\textsubscript{S}, aac(6\textsuperscript{'})-Ib-cr, qep\textsubscript{A}, oqxA and oqxB, with the previously described primers [37–43].

4.4. Screening for Plasmid-Mediated Resistance Genes

Antimicrobial susceptibility was tested by the disk diffusion method and interpreted according to the French Society for Microbiology (SFM) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [44]. The antibiotic disks (Bio-Rad\textsuperscript{®}, Marnes-La-Coquette, France) tested included amoxicillin plus clavulanic acid, ampicillin, cefalexin, cefepime, cefotaxime, cefuroxime, chloramphenicol, ciprofloxacin, erythromycin, gentamicin, nalidixic acid, streptomycin, sulfonamides, tetracycline and trimethoprim.

4.5. PFGE Typing

E. coli strains were typed using PFGE on XbaI-digested DNA following the CDC-standard operating procedure [45]. Analysis was conducted using BioNumerics software. A Dice similarity coefficient with a UPGMA dendrogram was generated based on 1% tolerance windows and 1% optimization. A cutoff line at 95% was considered to identify genetically related isolates.

Author Contributions: Conceptualization, M.M.U., F.A., H.B. and D.B.; investigation, M.M.U., V.D., N.A. and C.B.-T.; resources, M.M.U., V.D. and N.A.; writing—original draft preparation, M.M.U., V.D., F.A. and D.B.; writing—review and editing, M.M.U., V.D., F.A., E.O., H.B. and D.B.; visualization, M.M.U. and D.B.; supervision, H.B. and D.B.; project administration, H.B. and D.B.; funding acquisition, C.B.-T., H.B. and D.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the French Ministry of Agriculture and Food.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We would like to thank Monique Kérourédan (ENVT, Toulouse) for her technical assistance and Emeline Lhuillier (GeT-Purpan, GenoToul, Toulouse, France) for sequencing experiments. We would also like to thank Marie Drouet, Estelle Freycon and Laurent Allais (Institut de l’Elevage, Villers-Bocage) for collecting feces at the time of slaughter. We wish to express our gratitude to Olivier Barraud (CHU Limoges), Richard Bonnet and Frederic Robin (CHU Clermont-Ferrand), Laurent Cavalie (IFB, CHU-Purpan, Toulouse, France), Surbhi Malhotra-Kumar (Universiteit Antwerpen, Belgium) and Valeria Bortolaia (National Food Institute, Technical University of Denmark) for kindly providing the PMQR genes, mcr-1-, mcr-2- and mcr-3-harboring strains.

Conflicts of Interest: The authors declare no conflict of interest.
Antibiotics 2022, 11, 1071

23. Haenni, M.; Beyrouthy, R.; Lupo, A.; Châtre, P.; Madec, J.-Y.; Bonnet, R. Epidemic spread of Escherichia coli ST744 isolates carrying mcr-3 and blaCTX-M-55 in cattle in France. J. Antimicrob. Chemother. 2018, 73, 533–536. [CrossRef]

24. Haenni, M.; Métayer, V.; Gay, E.; Madec, J.-Y. Increasing Trends in mcr-1 Prevalence among Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from French Calves despite Decreasing Exposure to Colistin. Antimicrob. Agents Chemother. 2016, 60, 6433–6434. [CrossRef]

25. Khine, N.O.; Lugosmya, K.; Niyomtham, W.; Pongpan, T.; Hampson, D.J.; Prapasarakul, N. Longitudinal Monitoring Reveals Persistence of Colistin-Resistant Escherichia coli on a Pig Farm Following Cessation of Colistin Use. Front. Vet. Sci. 2022, 9, 845746. [CrossRef] [PubMed]

26. Mead, A.; Billon-Lotz, C.; Olsen, R.; Swift, B.; Richez, P.; Stabler, R.; Pelligand, L. Epidemiological Prevalence of Phenotypical Resistances and Mobilised Colistin Resistance in Avian Commensal and Pathogenic E. coli from Denmark, France, The Netherlands, and the UK. Antibiotics 2022, 11, 631. [CrossRef]

27. Zhang, J.; Zheng, B.; Zhao, L.; Wei, Z.; Ji, J.; Li, L.; Xiao, Y. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect. Dis. 2014, 14, 659. [CrossRef]

28. Birgy, A.; Madhi, F.; Hogan, J.; Doit, C.; Gaschignard, J.; Caseris, M.; Bidet, P.; Cohen, R.; Bonacorsi, S. CTX-M-55-, MCR-1-, and FosA-Producing Multidrug-Resistant Escherichia coli Infection in a Child in France. Antimicrob. Agents Chemother. 2018, 62, e00127-18. [CrossRef]

29. Gay, E.; Bour, M.; Cazeau, G.; Jarrige, N.; Martineau, C.; Madec, J.-Y.; Haenni, M. Antimicrobial Usages and Antimicrobial Resistance in Avian or Fecal Escherichia coli From Veal Calves in France: Evolution During the Fattening Process. Front. Microbiol. 2019, 10, 792. [CrossRef]

30. Walsh, T.R.; Wu, Y. China bans colistin as a feed additive for animals. Lancet Infect. Dis. 2016, 16, 1102–1103. [CrossRef]

31. Lay, K.; Jeamsripong, S.; Sunn, K.; Angkititrakul, S.; Prathan, R.; Srisanga, S.; Chuanchuen, R. Colistin Resistance and ESBL Production in Salmonella and Escherichia coli from Pigs and Pork in the Thailand, Cambodia, Lao PDR, and Myanmar Border Area. Antibiotics 2021, 10, 657. [CrossRef]

32. Randall, L.; Horton, R.; Lemma, F.; Martelli, F.; Duggett, N.A.; Smith, R.; Kirchner, M.; Ellis, R.; Rogers, J.P.; Williamson, S.; et al. Longitudinal study on the occurrence in pigs of colistin-resistant Escherichia coli carrying mcr-1 following the cessation of use of colistin. J. Appl. Microbiol. 2018, 125, 596–606. [CrossRef]

33. Wang, Y.; Xu, C.; Zhang, R.; Chen, Y.; Shen, Y.; Hu, F.; Liu, D.; Lu, J.; Guo, Y.; Xia, X.; et al. Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: An epidemiological comparative study. Lancet Infect. Dis. 2020, 20, 1161–1171. [CrossRef]

34. Versalovic, J.; Koeth, T.; Lupski, J.R. Distribution of Repetitive DNA Sequences in Eubacteria and Application to Fingerprinting of Bacterial Genomes. Nucleic Acids Res. 1991, 19, 6823–6831. [CrossRef] [PubMed]

35. EURL-AL European Union Reference Laboratory Antimicrobial Resistance. PCR for Plasmid-Mediated Colistin Resistance Genes Mcr-1 and Mcr-2 (Multiplex). October 2016, Version 2; European Union: Maastricht, The Netherlands, 2016.

36. Dallenne, C.; Da Costa, A.; Decrét, D.; Favier, C.; Arlet, G. Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother. 2010, 65, 490–495. [CrossRef]

37. Cattoir, V.; Poirel, L.; Nordmann, P. Plasmid-Mediated Quinolone Resistance Pump QepA2 in an Escherichia coli Isolate from France. Antimicrob. Agents Chemother. 2008, 52, 3801–3804. [CrossRef] [PubMed]

38. Cattoir, V.; Poirel, L.; Rotimi, V.; Soussy, C.-J.; Nordmann, P. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J. Antimicrob. Chemother. 2007, 60, 394–397. [CrossRef]

39. Cavaco, I.M.; Hasman, H.; Xia, S.; Aarestrup, F.M. qnrD, a Novel Gene Conferring Transferable Quinolone Resistance in Salmonella enterica Serovar Kentucky and Bovismorbidicas Strains of Human Origin. Antimicrob. Agents Chemother. 2009, 53, 603–606. [CrossRef]

40. Chen, X.; Zhang, W.; Pan, W.; Yin, J.; Pan, Z.; Gao, S.; Jiao, X. Prevalence of qnr, aac(6′)-Ib-cr, qepA, and oqxAB in Escherichia coli Isolates from Humans, Animals, and the Environment. Antimicrob. Agents Chemother. 2012, 56, 3423–3427. [CrossRef]

41. Park, C.H.; Robicsek, A.; Jacoby, G.A.; Sahm, D.; Hooper, D.C. Prevalence in the United States of aac(6′)-Ib-cr Encoding a Ciprofloxacin-Modifying Enzyme. Antimicrob. Agents Chemother. 2006, 50, 3953–3955. [CrossRef]

42. Robicsek, A.; Strahleivitz, J.; Sahm, D.F.; Jacoby, G.A.; Hooper, D.C. qnr Prevalence in Ceftazidime-Resistant Enterobacteriaceae Isolates from the United States. Antimicrob. Agents Chemother. 2006, 50, 2872–2874. [CrossRef] [PubMed]

43. Wang, M.; Guo, Q.; Xu, X.; Wang, X.; Ye, X.; Wu, S.; Hooper, D.C.; Wang, M. New Plasmid-Mediated Quinolone Resistance Gene, qnrC, Found in a Clinical Isolate of Proteus mirabilis. Antimicrob. Agents Chemother. 2009, 53, 1892–1897. [CrossRef] [PubMed]

44. CA-SFM Comité de l’antibiogramme de la Société Française de Microbiologie. Recommandations 2016. V1.0; CA-SFM Comité de l’antibiogramme de la Société Française de Microbiologie: Paris, France, 2016.

45. CDC PN105. Standard Operating Procedure for PulseNet PFGE of Escherichia Coli O157:H7, Escherichia Coli Non-O157 (STEC), Salmonella Serotypes, Shigella Sonnei and Shigella Flexneri. 2017. Available online: https://www.cdc.gov/pusnet/pdf/coli-shigella-salmonella-pfge-protocol-508c.pdf (accessed on 1 July 2018).